KAS
NPCE icon

Kemnay Advisory Services’s Neuropace NPCE Stock Holding History

Kemnay Advisory Services’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$59.5K Buy
4,522
+3,869
+592% +$58K 0.01% 223
2025
Q4 		$10.1K Buy
+653
New +$8.73K ﹤0.01% 747

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Kemnay Advisory Services's NPCE Position: Q1 2026 in Review

Kemnay Advisory Services increased its Neuropace (NPCE) stake by 592% in Q1 2026, buying an estimated $58K and bringing the position to 4,522 shares worth $59.5K. The position accounts for 0.01% of the portfolio, ranked #223.

Kemnay Advisory Services first reported a position in NPCE in Q4 2025 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Kemnay Advisory Services held 4,522 shares of Neuropace worth $59.5K as of Q1 2026.
  • Kemnay Advisory Services bought 3,869 Neuropace shares in Q1 2026, an estimated $58K.
  • Neuropace made up 0.01% of Kemnay Advisory Services's portfolio in Q1 2026, its #223 holding.
  • Kemnay Advisory Services first reported a position in Neuropace in Q4 2025 and has held it in 2 quarters since.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Kemnay Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.